Skip Ribbon Commands
Skip to main content
A- A A+

Find a Doctor

Prof Chng Wee Joo

Designations:
  • Senior Consultant, Division of Haematology, Department of Haematology-Oncology, National University Cancer Institute, Singapore
  • Professor, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore
  • Provost's Chair Professor, Yong Loo Lin School of Medicine, National University of Singapore
  • ​Vice President (Biomedical Sciences Research), Office of the Deputy President (Research and Technology), National University of Singapore
  • Group Director, NUHS Research Office
Qualifications:
MB ChB, PhD, FRCP (UK), FRCPath (UK), FAMS
Specialties:
Haematology
Special Interests:
Multiple Myeloma, Lymphoma

Biosketch

Prof Chng obtained his medical degree from the University of Leeds, UK, and did his internal medicine residency in the United Kingdom. His fellowship training in haematology was completed in Singapore before he obtained an A*STAR international fellowship in 2004 for a research fellowship in multiple myeloma genetics at the Mayo Clinic. His current research is very translational and involves the use of high-resolution global genomic techniques to understand biology, identify drug targets, understand drug resistance and improve disease prognosis in haematological malignancies, with the ultimate aim of improving patient outcomes and personalising treatment.

Awards

  • 2021 - Yong Loo Lin School of Medicine Graduate Mentor of the Year (GRAMAY) Award
  • 2020 - Brian G.M. Durie Outstanding Achievement Award
  • 2020 - National Day Awards - Public Administration Medal (Silver)
  • 2017 - NUS YLL SOM Outstanding Researcher of the Year Award
  • 2017 - NMRC Senior Translational (STaR) Research Award
  • 2016 - 26th Seah Cheng Siang Memorial Lecture
  • 2016 - NMEA National Outstanding Clinician-Scientist Award

Journals & Publications

  1. Chng WJ, Goldschmidt H, Dimopoulos MA, Moreau P, Joshua D, Palumbo A, Facon T, Ludwig H, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Gillenwater HH, Mohamed N, Feng S, Aggarwal S, Hájek R. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia. 2017 Jun;31(6):1368-1374.
  2. Ng SB, Chung TH, Kato S, Nakamura S, Takahashi E, Ko YH, Khoury JD, Yin CC, Soong R, Jeyasekharan AD, Hoppe MM, Selvarajan V, Tan SY, Lim ST, Ong CK, Nairismägi ML, Maheshwari P, Choo SN, Fan S, Lee CK, Chuang SS, Chng WJ. Epstein-Barr virus-associated primary nodal T/NK-cell lymphoma shows a distinct molecular signature and copy number changes. Haematologica. 2018 Feb;103(2):278-287.
  3. Teoh PJ, An O, Chung TH, Chooi JY, Toh SHM, Fan S, Wang W, Koh BTH, Fullwood MJ, Ooi MG, de Mel S, Soekojo CY, Chen L, Ng SB, Yang H, Chng WJ. Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis. Blood. 2018 Sep 20;132(12):1304-1317.
  4. Xie Z, Chooi JY, Toh SHM, Yang D, Basri NB, Ho YS, Chng WJ. MMSET I acts as an oncoprotein and regulates GLO1 expression in t(4;14) multiple myeloma cells. Leukemia. 2019 Mar;33(3):739-748.
  5. Chong PSY, Zhou J, Lim JSL, Hee YT, Chooi JY, Chung TH, Tan ZT, Zeng Q, Waller DD, Sebag M, Chng WJ. IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma. Cancer Res. 2019 Sep 15;79(18):4679-4688.
  6. Teoh PJ, Chung TH, Chng PYZ, Toh SHM, Chng WJ. IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification. Haematologica. 2020 May;105(5):1391-1404.
  7. Li B, Yan J, Phyu T, Fan S, Chung TH, Mustafa N, Lin B, Wang L, Eichhorn PJA, Goh BC, Ng SB, Kappei D, Chng WJ. MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphoma. Blood. 2019 Dec 5;134(23):2046-2058.
  8. Soekojo CY, Kim K, Huang SY, Chim CS, Takezako N, Asaoku H, Kimura H, Kosugi H, Sakamoto J, Gopalakrishnan SK, Nagarajan C, Wei Y, Moorakonda R, Lee SL, Lee JJ, Yoon SS, Kim JS, Min CK, Lee JH, Durie B, Chng WJ. Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network. Blood Cancer J. 2019 Oct 8;9(10):83.
  9. Jia Y, Zhou J, Tan TK, Chung TH, Wong RWJ, Chooi JY, Lim JSL, Sanda T, Ooi M, De Mel S, Soekojo C, Chen Y, Zhang E, Cai Z, Shen P, Ruan J, Chng WJ. Myeloma-specific superenhancers affect genes of biological and clinical relevance in myeloma. Blood Cancer J. 2021 Feb 12;11(2):32
  10. Chong PSY, Chooi JY, Lim JSL, Toh SHM, Tan TZ, Chng WJ. SMARCA2 Is a Novel Interactor of NSD2 and Regulates Prometastatic PTP4A3 through Chromatin Remodeling in t(4;14) Multiple Myeloma. Cancer Res. 2021 Feb 18.

Professional Memberships

  • American Society of Haematology
  • American Association of Cancer Research
  • International Myeloma Working Group
  • Asian Myeloma Network
  • Singapore Society of Haematology


 

Back to Top